These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 330972)

  • 1. Specific immunotherapy with neuraminidase-modified leukemic cells: experimental and clinical trials.
    Bekesi JG; Holland JF; Roboz JP
    Med Clin North Am; 1977 Sep; 61(5):1083-100. PubMed ID: 330972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effectiveness of neuraminidase-treated tumor cells as an immunogen in man and experimental animals with leukemia.
    Bekesi JG; Roboz JP; Holland JF
    Ann N Y Acad Sci; 1976; 277(00):313-31. PubMed ID: 1069551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active immunotherapy in leukemia with neuraminidase-modified leukemic cells.
    Bekesi JG; Holland JF
    Recent Results Cancer Res; 1977; (62):78-89. PubMed ID: 203005
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of spontaneous leukemia in AKR mice with chemotherapy, immunotherapy, or interferon.
    Bekesi JG; Roboz JP; Zimmerman E; Holland JF
    Cancer Res; 1976 Feb; 36(2 pt 2):631-9. PubMed ID: 1082796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of specific immunotherapy in acute myelocytic leukemia.
    Bekesi JG; Holland JF
    Haematol Blood Transfus; 1979; 23():79-87. PubMed ID: 161758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of leukemia and lymphoma.
    Murphy S; Hersh E
    Semin Hematol; 1978 Apr; 15(2):181-203. PubMed ID: 418506
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotherapy of human leukemia with neuraminidase-modified cells.
    Holland JF; Bekesi JG
    Med Clin North Am; 1976 May; 60(3):539-49. PubMed ID: 1063908
    [No Abstract]   [Full Text] [Related]  

  • 8. Discussion paper: experimental and clinical immunopharmacology data applicable to cancer immunotherapy.
    Mathé G; Schwarzenberg L; Halle-Pannenko O; Simmler MC
    Ann N Y Acad Sci; 1976; 277(00):467-84. PubMed ID: 826207
    [No Abstract]   [Full Text] [Related]  

  • 9. Active immunotherapy of AkR mice spontaneous leukemia.
    Mathé G; Halle-Pannenko O; Bourut C
    Rev Eur Etud Clin Biol; 1972 Dec; 17(10):997-1000. PubMed ID: 4660002
    [No Abstract]   [Full Text] [Related]  

  • 10. Prolonged survival in long-passage AKR leukemia using chemotherapy, radiotherapy, and adoptive immunotherapy.
    Bortin MM; Rimm AA; Rodey GE; Giller R; Saltzstein EC
    Cancer Res; 1974 Aug; 34(8):1851-6. PubMed ID: 4152270
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic effectiveness of neuraminidase-treated allogeneic myeloblasts as immunogen in acute myelocytic leukemia.
    Bekesi JG; Holland JF
    Recent Results Cancer Res; 1982; 80():42-55. PubMed ID: 6800000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoimmunotherapy in human and experimental leukemia.
    Bekesi JG; Roboz JP; Holland JF
    Bibl Haematol; 1975 Oct; (43):524-5. PubMed ID: 1067089
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunology and colonic cancer: cancer immunotherapy results in leukemias--experimental and clinical approaches to the treatment of solid tumors.
    Mathé G; Thompson RB
    Dis Colon Rectum; 1973; 16(5):341-57. PubMed ID: 4590448
    [No Abstract]   [Full Text] [Related]  

  • 14. Potentiation of concanavalin A-bound L1210 vaccine in vivo by chemotherapeutic agents.
    Kataoka T; Kobayashi H; Sakurai Y
    Cancer Res; 1978 May; 38(5):1202-7. PubMed ID: 639053
    [No Abstract]   [Full Text] [Related]  

  • 15. [Evaluation of leukemogenic and immunogenic properties of leukemic cells modified by neuraminidase of non-cholera Vibrios on the model of Rauscher leukemia].
    Bratus GG; Darchuk GF
    Eksp Onkol; 1985; 7(2):56-60. PubMed ID: 3874054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCG in cancer immunotherapy: experimental and clinical trials of its use in treatment of leukemia minimal and or residual disease.
    Mathé G; Weiner R; Pouillart P; Schwarzenberg L; Jasmin C; Schneider M; Hayat M; Amiel JL; de Vassal F; Rosenfeld C
    Natl Cancer Inst Monogr; 1973 Dec; 39():165-75. PubMed ID: 4595314
    [No Abstract]   [Full Text] [Related]  

  • 17. Active immunotherapy in the treatment of experimental leukemias and acute lymphoblastic leukemia in man.
    Mathé G; Hayat M; Amiel JL; Schwarzenberg L; Schneider M; Pouillart P; Cattan A
    Boll Ist Sieroter Milan; 1971; 50(4):251-9. PubMed ID: 5293498
    [No Abstract]   [Full Text] [Related]  

  • 18. Natural polyclonality of spontaneous AKR leukemia and its consequences for so-called specific immunotherapy.
    Olsson L; Ebbesen P
    J Natl Cancer Inst; 1979 Mar; 62(3):623-7. PubMed ID: 84093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft versus leukemia. VI. Adoptive immunotherapy in combination with chemoradiotherapy for spontaneous leukemia-lymphoma in AKR mice.
    Bortin MM; Rose WC; Truitt RL; Rimm AA; Saltzstein EC; Rodey GE
    J Natl Cancer Inst; 1975 Nov; 55(5):1227-9. PubMed ID: 1546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of L1210 leukemia using neuraminidase-modified plasma membranes combined with chemotherapy.
    Pincus JH; Jameson AK; Brandt AE
    Cancer Res; 1981 Aug; 41(8):3082-6. PubMed ID: 7248965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.